Member Info for DireCons

Https://www.eifron.com/en/

Https://probiotixhealth-ir.com/news/archive/2024/160924

New Commercial Partnership in Greece

16 September 2024

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Greece based consumer brands specialist Eifron SA ("Eifron").

As part of the terms of the agreement, Eifron will introduce YourBiotixBP tablets, containing LPLDL®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in Q1 2025. Through this strategic partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LPLDL®. The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.

ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and thereafter in selected regions in Europe.

Founded in 2011, Eifron specialises in innovative healthcare solutions and holds a strong market position, particularly in Greece where it is among the top five brands in the country. Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.

Steen Andersen, CEO of ProBiotix, commented: "This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe.

"Eifron's reputation and expertise in the health sector and their commitment to natural solutions makes them an ideal partner for us."

Elias Kartasiadis, CEO of Eifron, added: "We are thrilled to partner with ProBiotix Health and bring their scientifically-backed products to our markets. This partnership aligns perfectly with our mission to provide our customers with effective and natural health solutions.

"We believe this collaboration will help us expand our reach and offer differentiation and added value to the growing group of consumers looking to improve their cardiometabolic health."

Nowadays?

A crime

Was

Stalking

I thought

Creepy.

Really

Just

It's

Why does the troll need multiple posts when one will do?

I do hope it is being paid per post for stalking.

Indeed. This bb is an oasis of sanity compared to other places.

I just can't fathom what this clown hopes to achieve by his ridiculous actions.

LSE are usually pretty good with taking out the trash.

He won't be here long.

Yes, and from that presentation is worth a re-read.

Partner agreements

The Company has been working with a wide range of industry partners since 2020 and has Material Transfer Agreements ("MTA"), and/or Non-Disclosure Agreements ("NDA"), and/or Open innovation arrangements with well-known consumer brands like Kellogg's, Nestle, Coca Cola, Cargill and more specialised sweetener and fibre groups like Tereos, Givaudan, Sudzucker, Puratos and Firmench. These agreements allow us to share information and products whilst protecting our intellectual property and partners to receive information and different SweetBiotix® products to test within their product ranges. This allows them to assess texture, taste, stability, and how they would incorporate Sweetbiotix® into their product manufacturing processes.

We developed SweetBiotix® in the laboratory and have been working on novel methods to scale up the manufacturing process to produce at industrial scale to supply large partners whilst having the same structural, prebiotic function, and taste and texture. We have been doing this through two different agreements for two different types of SweetBiotix®. These are:-

1. A manufacturing agreement signed with a US partner in September 2020. They are paying OptiBiotix a six figure annual milestone in H2 every year during scale up plus a six figure launch milestone payment with royalties of 5% on all sales and a further 5% on sales to 11 named companies (Kelloggs, Nestle, Coca Cola , Firmenich, Tereos, Cargill, Arla ,Tate and Lyle, Agropur, Givaudan, Tata) reflecting the development work ongoing with these partners before we signed the agreement.

2. An agreement was signed with Firmenich in July 2022 to optimise scale up and development of another type of SweetBiotix®. They will pay OptiBiotix a six figure payment per market approval (USA/Europe/Asia) plus royalties and additional milestones on sales. As previously disclosed, Firmenich are one of the world leaders in taste and the world's largest stevia supplier. Their turnover is around £3.6bn per year which has risen to US $11.4bn annual turnover following their merger with DSM, and are now known as DSM Firmenich. They are experts in their field and chose SweetBiotix® after an 18 month due diligence process. This agreement with one of the leaders in the field after extensive due diligence of the science, taste, and intellectual property, is a substantial validation of the SweetBiotix® science and commercial potential.

I suppose if they list ALL the major players involved in the same RNS there's no conflict. The confidentiality would be to protect what actual products they are applied to and launch dates?

Gobbygnome

Member Since

11th Sep 2024

Don't invest then dumbo. Yet another troll alias for the bin.

Yeah, OPTI not for you it seems. Aww, what a shame, all that time and effort . Good luck on your next trolling venture.

One more for the bin.

I've got a question.

'IF' you could buy at 3.35p or thereabouts, (BIG ask) would you follow Frederik Bruhn-Petersen and his family and invest more in PBX? The family are obviously no fools when it comes to investment.

Thoughts please?

So DSM-Firmenich don't exist, and they aren't scaling up bulk manufacture of Sweetbiotix, which also doesn't exist?

Ok thanks. I'll have to re-evaluate my investment due to your concerns.